Q32 Bio, Inc. (QTTB)
8.34
+0.25
(+3.09%)
USD |
NASDAQ |
Oct 09, 16:00
8.31
-0.03
(-0.36%)
Pre-Market: 20:00
Q32 Bio Cash from Operations (Quarterly) : -3.075M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -3.075M |
| March 31, 2026 | -6.343M |
| December 31, 2025 | -6.18M |
| September 30, 2025 | -4.23M |
| June 30, 2025 | -10.65M |
| March 31, 2025 | -12.48M |
| December 31, 2024 | -11.43M |
| September 30, 2024 | -19.52M |
| June 30, 2024 | -22.21M |
| March 31, 2024 | -14.55M |
| December 31, 2023 | -10.72M |
| September 30, 2023 | 15.90M |
| June 30, 2023 | -11.37M |
| March 31, 2023 | -12.50M |
| December 31, 2022 | -27.20M |
| September 30, 2022 | -24.93M |
| June 30, 2022 | -30.85M |
| March 31, 2022 | -30.68M |
| Date | Value |
|---|---|
| December 31, 2021 | -30.43M |
| September 30, 2021 | -25.39M |
| June 30, 2021 | -24.11M |
| March 31, 2021 | -29.82M |
| December 31, 2020 | -11.61M |
| September 30, 2020 | -28.89M |
| June 30, 2020 | -27.99M |
| March 31, 2020 | -25.85M |
| December 31, 2019 | -26.33M |
| September 30, 2019 | -25.48M |
| June 30, 2019 | -21.67M |
| March 31, 2019 | -17.87M |
| December 31, 2018 | -8.079M |
| September 30, 2018 | -13.69M |
| June 30, 2018 | -9.747M |
| March 31, 2018 | -11.04M |
| December 31, 2017 | 22.05M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Intellia Therapeutics, Inc. | -83.11M |
| Beam Therapeutics, Inc. | -66.10M |
| Prime Medicine, Inc. | -41.05M |
| Prelude Therapeutics, Inc. | -15.57M |
| Twist Bioscience Corp. | 1.115M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Financing (Quarterly) | 58.59M |
| Free Cash Flow | -19.83M |
| Free Cash Flow Per Share (Quarterly) | -0.1512 |
| Free Cash Flow to Equity (Quarterly) | 5.275M |
| Free Cash Flow to Firm (Quarterly) | -2.275M |
| Free Cash Flow Yield | -16.04% |